Literature DB >> 2274658

Clinical features and natural history of von Hippel-Lindau disease.

E R Maher1, J R Yates, R Harries, C Benjamin, R Harris, A T Moore, M A Ferguson-Smith.   

Abstract

The clinical features, age at onset and survival of 152 patients with von Hippel-Lindau disease were studied. Mean age at onset was 26.3 years and 97 per cent of patients had presented by aged 60 years. Retinal angioma was the first manifestation in 65 patients (43 per cent), followed by cerebellar haemangioblastoma (n = 60, 39 per cent) and renal cell carcinoma (n = 15, 10 per cent). Overall, 89 patients (59 per cent) developed a cerebellar haemangioblastoma, 89 (59 per cent) a retinal angioma, 43 (28 per cent) renal cell carcinoma, 20 (13 per cent) spinal haemangioblastoma and 11 (7 per cent) a phaeochromocytoma. Renal, pancreatic and epididymal cysts were frequent findings but their exact incidence was not accurately assessed. Mean age at diagnosis of renal cell carcinoma (44.0 +/- 10.9 years) was significantly older than that for cerebellar haemangioblastoma (29.0 +/- 10.0 years) and retinal angioma (25.4 +/- 12.7 years). The probability of a patient with von Hippel-Lindan disease developing a cerebellar haemangioblastoma, retinal angioma or renal cell carcinoma by age 60 years was 0.84, 0.7 and 0.69, respectively. A comprehensive screening protocol for affected patients and at-risk relatives is presented, based on detailed analysis of age at onset data for each of the major complications. Median actuarial survival was 49 years, with renal cell carcinoma the leading cause of death.

Entities:  

Mesh:

Year:  1990        PMID: 2274658     DOI: 10.1093/qjmed/77.2.1151

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  207 in total

1.  Long-term stability after multilevel cervical laminectomy for spinal cord tumor resection in von Hippel-Lindau disease.

Authors:  Ashok R Asthagiri; Gautam U Mehta; John A Butman; Martin Baggenstos; Edward H Oldfield; Russell R Lonser
Journal:  J Neurosurg Spine       Date:  2011-01-28

2.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 3.  Von Hippel-Lindau disease.

Authors:  E R Maher; A T Moore
Journal:  Br J Ophthalmol       Date:  1992-12       Impact factor: 4.638

Review 4.  An update on the genetics of pheochromocytoma.

Authors:  D Karasek; U Shah; Z Frysak; C Stratakis; K Pacak
Journal:  J Hum Hypertens       Date:  2012-05-31       Impact factor: 3.012

5.  Pancreatic Cyst Fluid Vascular Endothelial Growth Factor A and Carcinoembryonic Antigen: A Highly Accurate Test for the Diagnosis of Serous Cystic Neoplasm.

Authors:  Rosalie A Carr; Michele T Yip-Schneider; Scott Dolejs; Bradley A Hancock; Huangbing Wu; Milan Radovich; C Max Schmidt
Journal:  J Am Coll Surg       Date:  2017-05-18       Impact factor: 6.113

6.  Single-stage laparoscopic adrenalectomy for pheochromocytoma and enucleation of a pancreatic neuroendocrine tumor in Von Hippel-Lindau disease: A case report.

Authors:  Marco Casaccia; Simona Macina; Rosario Fornaro
Journal:  Mol Clin Oncol       Date:  2017-04-06

7.  Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.

Authors:  Chi-Chao Chan; Youn-Soo Lee; Zhengping Zhuang; Joseph Hackett; Emily Y Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2004

8.  Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

Authors:  Á Ordóñez-Navadijo; E Fuertes-Yebra; B Acosta-Iborra; E Balsa; A Elorza; J Aragonés; M O Landazuri
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  Hereditary renal cell carcinoma associated with von Hippel-Lindau disease: a description of a Nova Scotia cohort.

Authors:  Shannon Bradley; Nadine Dumas; Mark Ludman; Lori Wood
Journal:  Can Urol Assoc J       Date:  2009-02       Impact factor: 1.862

10.  Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect.

Authors:  H Brauch; T Kishida; D Glavac; F Chen; F Pausch; H Höfler; F Latif; M I Lerman; B Zbar; H P Neumann
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.